Navigation Links
Long-term Use of Antiepileptic Drug Vimpat® (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
Date:12/5/2011

ATLANTA, Dec. 5, 2011 /PRNewswire/ -- UCB today announced new findings for Vimpat® (lacosamide) C-V that offer additional support regarding the long-term effects of the antiepileptic drug (AED) as an adjunctive therapy for adults with uncontrolled partial-onset seizures.  The data demonstrate reduced seizure severity and improvements in measures of health-related quality of life (HRQoL).  These and other Vimpat® data were presented at the 65th Annual Meeting of the American Epilepsy Society (AES) in Baltimore, Md.

Analyses of pooled data from open-label extensions of several Phase II/III trials showed that treatment with lacosamide was generally well-tolerated and associated with decreased partial-onset seizures for up to eight years. 

"Collectively, this body of evidence showed that lacosamide reduced seizure frequency and improved health-related quality of life, as reported by patients.  And these effects were maintained over a long-term basis," said Dr. William Rosenfeld, M.D., Director, The Comprehensive Epilepsy Care Center for Children and Adults, St. Louis, Mo.

Additional analyses of pooled data from open-label extensions of several Phase II/III trials highlighted patients' self-reported improvements in HRQoL during long-term treatment with lacosamide.  Specific areas of improvements reported by patients were seizure worry and social functioning.  Patients also consistently reported feelings of improvements in their overall health state.

Vimpat® is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy.  The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of Vimpat®-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.  Additional important safety information for Vimpat® is available at the end of the press release.

Data pre
'/>"/>

SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Merz research Shows Long-term Benefits for Patients With Dystonia
3. AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions
4. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
5. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
6. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
7. Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
8. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
9. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
10. Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology
11. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Mass. , Aug. 28, 2014  Seres ... for diseases related to the human microbiome, announced ... Executive Vice President of R&D and Chief Scientific ... Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The ... of SER-109, a novel mixture of bacterial spores ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Markets to 2020 - Novel Therapeutic ... Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics in ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Therapeutics to 2020 - Broadened Diagnostic ... Drive Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8
... , JOHANNESBURG, South Africa, Nov. 26 ... the Year Award in the Generic Pharmaceutical Market is ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , For the Company of the ... Cipla Medpro,s performance against key competitors: growth strategy and ...
... , BEDFORD, Mass., Nov. 25 Hologic, Inc. ... developer, manufacturer and supplier of premium diagnostics, medical imaging systems ... women, is using the annual meeting of the Radiological Society ... 29 through December 3, 2009 to highlight our new SecurView(®) ...
Cached Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4
(Date:8/29/2014)... August 29, 2014 Parker Waichman LLP, ... to protecting the rights of victims who have been ... (DEA) has announced new regulations for all hydrocodone combination ... (RAPS) report dated August 21, 2014, the DEA ... drugs under federal law. , The long-awaited announcement ...
(Date:8/29/2014)... Bedros Keuilian recently stepped outside his comfort zone to ... the new Spike TV reality show, Gym Rescue. The producers ... an expert in boot camp marketing and Google directed them ... just released a webinar explaining how fitness boot camp owners ... and increase their client base. , In the hour-long ...
(Date:8/29/2014)... 29, 2014 Hastings and Hastings, a ... clients’ money for many years is pleased to report ... $190,000. With 11 convenient locations throughout the Valley, Hastings ... by a licensed attorney. In addition, experienced personal injury ... This level of dedication and service is indicative of ...
(Date:8/29/2014)... "I have had many hospital stays, including five ... other surgeries in my lifetime, as I am a burn ... I was unable to move freely in order to prevent ... had to physically rotate me every 30 minutes to 2 ... pulled the sheets. This was jarring and caused me major ...
(Date:8/29/2014)... 2014 Many Americans are diagnosed with ... type 2 at bay, patients should consider this an ... necessary lifestyle changes. While some diabetes risk factors are ... age, or belonging to certain ethnic groups, there is ... weight. Carrying extra pounds, especially in the abdomen, interferes ...
Breaking Medicine News(10 mins):Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 2Health News:Boot Camp Marketing Expert Bedros Keuilian Releases New Webinar on Using YouTube to Build Credibility and Clientele 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $20,900 On A Settlement Of $190,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $20,900 On A Settlement Of $190,000 3Health News:InventHelp® Client Develops Equipment for Surgical and Bedridden Patients (HCD-279) 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 3
... Ky., Dec. 23 A group representing some of the ... drop language that would require vending companies to disclose the ... the point of sale, Vend Marketing Institute (VMI) Executive Director ... both the House and Senate versions of the healthcare reform ...
... for King Herod Himself , WASHINGTON, Dec. 23 As ... Reid,s health care bill, Family Research Council Action (FRC Action) ... call campaign in six states -- Nebraska, Arkansas, Louisiana, South ... to contact their Senators and tell them "don,t trade the ...
... Female janitors, scientists among those at highest risk, study ... working women in the United States, teachers seem to ... defects, while those who work as janitors, scientists and ... The study looked at nearly 9,000 babies born with ...
... ... conference provides First Responders with professional education and networking opportunity. , ... (PRWEB) December 23, ... Responders with professional education and networking opportunity., , ,Against a background of threats ...
... ... provider, today announced the appointment of a new leader who will help expand its ... ... debate rages on all sides of healthcare reform, one fact remains: the heavy lifting ...
... A McMaster University researcher has found the first evidence ... in car exhaust fumes and industrial air pollution can lead ... Infectious disease specialist Mark Loeb led a research team ... and sulfur dioxide, both found in motor vehicle emissions, and ...
Cached Medicine News:Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 2Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 3Health News:FRC Action Launches Last Minute Phone Call Campaign in Six States 2Health News:Mom's Job Could Boost Baby's Odds for Birth Defect 2Health News:5th Annual Homeland Security Professionals Conference and Exposition in Vegas on October 25-29 2010 2Health News:5th Annual Homeland Security Professionals Conference and Exposition in Vegas on October 25-29 2010 3Health News:New Executive Director to Lead Medical Education to Greater Relevance 2Health News:Air pollution linked to hospitalizations for pneumonia in seniors 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: